Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Profile Name||MAP2K1 K57T|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|MAP2K1 K57T||colorectal cancer||sensitive||Panitumumab + Trametinib||Case Reports/Case Series||Actionable||In a clinical case study, a combination of Vectibix (panitumumab) and Mekinist (trametinib) caused tumor regression in a patient’s colorectal cancer metastases harboring MAP2K1 K57T after being identified pre-clinically as a combination likely to inhibit MAP2K1 K57T expressing colorectal cancer (PMID: 26644315).||26644315|
|MAP2K1 K57T||colorectal cancer||resistant||Panitumumab||Preclinical||Actionable||In a preclinical study, a colorectal cancer cell line expressing MAP2K1 K57T was resistant to Vectibix (panitumumab) in culture (PMID: 26644315).||26644315|
|MAP2K1 K57T||colorectal cancer||predicted - resistant||Cetuximab||Case Reports/Case Series||Actionable||In a clinical case study, a patient with colorectal cancer developed liver metastases harboring MAP2K1 K57T that were insensitive to Erbitux (cetuximab) treatment and the mutation was confirmed to cause resistance in human colorectal cancer cell lines in culture (PMID: 26644315).||26644315|
|MAP2K1 K57T||colorectal cancer||sensitive||Cetuximab + Trametinib||Preclinical||Actionable||In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57T in culture (PMID: 26644315).||26644315|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|